Sign in
TerminatedNo phase

Mesenchymal Stem Cell Transplantation for Osteoarthritis

Key facts

Who runs it
Yantai Yuhuangding Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
2 people enrolled
Started
8 Jul 2019
Ended
28 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Auotologous BMSCs plus autologous PRP
  • Auotologous PRP
Record updated
24 January 2024
Why it stopped
Due to government regulation

Who can take part

Age
40 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Subject has Kellgren and Lawrence grade II-IV primary osteoarthritis as determined by X-ray
  • Subject's pain score is 8-13 points (Lequesne's index)
  • Ages between 40-70 years
  • Signed informed consent from the subject.-

Who cannot take part

  • Subject not suitable for bone marrow suction surgery
  • Subject's studied knee treated with intra-articular injection therapy within 6 months prior to screen
  • Subject has undergone surgery on studied knee, including fracture surgery, arthroscopic surgery, meniscus repair surgery, or cruciate ligament reconstruction surgery
  • Subject enrolled in any other cell therapy studies within the past 30 days
  • Subject infected with hepatitis B, hepatitis C, HIV, syphilis or HTLV
  • Subject with hypersensitivity/allergy to anesthetic
  • Subject has a history of gouty arthritis, septic arthritis, rheumatoid arthritis and any other autoimmune arthritis of the knee joint
  • Subject has had major medical problems in vital organs, such as; heart, liver, kidney, or lung.-
  • Subject's creatinine values higher than 1.6mg/dl
  • Subject with body mass index, BMI over 30
  • Subject who the investigator considers inappropriate for the clinical trial due to any other reasons than those listed above

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to explore the efficacy and safety of autologous bone marrow-derived mesenchymal stem cells (BMSCs) plus autologous platelet rich plasma (PRP) in the treatment of severe knee osteoarthritis.

The 2 groups in the trial

  • BMSCs plus PRP groupTreatment being tested

    Three intra-articular injections in total and autologous bone marrow-derived mesenchymal stem cells (BMSCs) suspended in 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.

    Treatment: Auotologous BMSCs plus autologous PRP

  • PRP groupExisting treatment, for comparison

    Three intra-articular injections in total and 3 ml autologous platelet rich plasma (PRP) for each injection. Time-points for intervention: 1) initial injection; 2) 3 months following initial injection; 3) 6 months following initial injection.

    Treatment: Auotologous PRP

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Autologous Mesenchymal Stem Cell Transplantation for the Treatment of Knee Osteoarthritis
Record updated
24 January 2024